Clinical Trials · NCT00381342
Safety and Efficacy of Exenatide as Monotherapy
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 233
- Start date
- Sep 2006
- Locations
- 19 sites, 5 countries
- Primary endpoint
- Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 24